The estimated Net Worth of William J Chase is at least $55.6 Million dollars as of 26 June 2019. Mr. Chase owns over 30,400 units of Abbvie Inc stock worth over $32,993,124 and over the last 12 years he sold ABBV stock worth over $13,909,612. In addition, he makes $8,724,790 as Executive Vice President - Finance and Administration at Abbvie Inc.
Sign up
Mr. Chase ABBV stock SEC Form 4 insiders trading
William has made over 10 trades of the Abbvie Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 30,400 units of ABBV stock worth $2,045,920 on 26 June 2019.
The largest trade he's ever made was selling 70,928 units of Abbvie Inc stock on 28 February 2018 worth over $8,311,343. On average, William trades about 9,498 units every 93 days since 2013. As of 26 June 2019 he still owns at least 169,552 units of Abbvie Inc stock.
You can see the complete history of Mr. Chase stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
William Chase biography
William J. Chase serves as Executive Vice President - Finance and Administration of the Company. He served as Abbott's Vice President, Licensing and Acquisitions from 2010 to 2012, as Vice President, Treasurer from 2007 to 2010, and as Divisional Vice President, Controller of Abbott International from 2004 to 2007. Mr. Chase joined Abbott in 1989.
What is the salary of William Chase?
As the Executive Vice President - Finance and Administration of Abbvie Inc, the total compensation of William Chase at Abbvie Inc is $8,724,790. There are 5 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.
How old is William Chase?
William Chase is 51, he's been the Executive Vice President - Finance and Administration of Abbvie Inc since 2018. There are 25 older and 5 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
What's William Chase's mailing address?
William's mailing address filed with the SEC is North Waukegan Road, North Chicago, Lake County, Illinois, 60088, United States.
Insiders trading at Abbvie Inc
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
What does Abbvie Inc do?
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
What does Abbvie Inc's logo look like?
Complete history of Mr. Chase stock trades at Intellia Therapeutics Inc and Abbvie Inc
Abbvie Inc executives and stock owners
Abbvie Inc executives and other stock owners filed with the SEC include:
-
Richard Gonzalez,
Chairman of the Board, Chief Executive Officer -
Laura Schumacher,
Vice Chairman, External Affairs and Chief Legal Officer -
Carlos Alban,
Vice Chairman, Chief Commercial Officer -
Michael Severino,
President, Vice Chairman -
Robert Michael,
Chief Financial Officer, Senior Vice President -
William Chase,
Executive Vice President - Finance and Administration -
Richard A. Gonzalez,
Chairman & CEO -
Dr. Michael E. Severino,
Vice Chairman & Pres -
Laura J. Schumacher,
Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. -
Timothy Richmond,
Chief Human Resource Officer, Executive Vice President -
Robert A. Michael,
Vice Chairman of Fin. & Commercial Operations and CFO -
Glenn Tilton,
Lead Independent Director -
Robert Alpern,
Independent Director -
Edward Rapp,
Independent Director -
Brett Hart,
Independent Director -
William Burnside,
Independent Director -
Roxanne Austin,
Independent Director -
Frederick Waddell,
Independent Director -
Melody Meyer,
Independent Director -
Edward Liddy,
Independent Director -
Thomas Freyman,
Independent Director -
Rebecca Roberts,
Independent Director -
Brian Durkin,
Vice President, Controller -
Jeffrey Stewart,
Senior Vice President, U.S. Commercial Operations -
Nicholas Donoghoe,
Senior Vice President - Enterprise Innovation -
Azita Saleki-Gerhardt,
Executive Vice President - Operations -
Henry Gosebruch,
Executive Vice President, Chief Strategy Officer -
Scott T. Reents,
Sr. VP & CFO -
Jeffrey Ryan Stewart,
Exec. VP & Chief Commercial Officer -
Henry O. Gosebruch,
Exec. VP & Chief Strategy Officer -
Scott C. Brun M.D.,
VP of Scientific Affairs & Head of AbbVie Ventures -
Timothy J. Richmond,
Exec. VP & Chief HR Officer -
Elizabeth Shea,
VP of Investor Relations -
Dr. Thomas J. Hudson,
Sr. VP of R&D and Chief Scientific Officer -
Dr. Azita Saleki-Gerhardt,
Exec. VP of Operations -
Thomas A. Hurwich,
VP, Controller -
Jennifer L. Davis,
-
Roy S Roberts,
Director -
Laboratories Abbott,
10% owner -
John M Leonard,
SVP, Chief Scientific Officer -
Elaine K. Sorg,
SVP, US COMMERCIAL OPERATIONS -
Perry C Siatis,
EVP, GC AND SECRETARY -
Carrie C Strom,
SVP & PRES GLOBAL ALLERG AESTH -
Thomas J Hudson,
SVP, CSO, GLOBAL RESEARCH -
Scott T Reents,
EVP, CHIEF FINANCIAL OFFICER -
Susan E Quaggin,
-
Kevin K Buckbee,
SVP, CONTROLLER -
Roopal Thakkar,
SVP, CMO, GLOBAL THERAPEUTICS